ExplainerMeasuring ageing

What a younger ageing-clock reading can tell us

An ageing clock converts biological measurements into a prediction. Its training target determines what that prediction means. A lower reading after an intervention still needs to be tested against lasting health outcomes.

Cell samples arranged beside a sculptural calibration instrument with nested plates.
An ageing clock turns biological measurements into a prediction based on its training data.

An ageing clock is a statistical model. Feed it measurements such as DNA methylation or blood proteins and it calculates an estimate. Some models estimate chronological age. Others were trained using mortality-related variables or changes observed over time.

The number has units that sound familiar, often years. That makes the output easy to read and easy to overinterpret. A predicted age is the model's summary of its inputs, interpreted against the data used to train it.

Horvath's 2013 methylation clock estimated age across many human tissues and cell types. Its performance showed that age-related information could be extracted from patterns of DNA methylation. The study did not establish that reducing the model's estimate through any intervention would extend life.

SchematicA clock produces a prediction
  1. Biological sampleA specified tissue and measurement time.
  2. Molecular measurementsFeatures supplied to the clock model.
  3. Predicted age or riskThe training target defines this output.

Clinical and functional outcomes require separate observations. Sources for this account.

Age, pace and the tissue sampled

An age estimate and a pace estimate describe different quantities. A clock that predicts age can report a change in years. A pace measure attempts to describe the rate of biological change. Comparing the outputs requires understanding what each model learned.

CALERIE provides a human example of clocks responding differently. A post hoc analysis of blood samples from its randomised calorie-restriction trial detected a change in DunedinPACE, while the reported PhenoAge and GrimAge estimates did not show significant treatment effects. The authors called for follow-up to determine whether the pace result would translate into disease prevention or longer healthy life.

Reporting only the most favourable clock conceals the disagreement. Readers need the prespecified outcomes and all relevant analyses.

Blood is convenient to collect, but it is a sample of a complex body. A change in circulating cells or proteins can alter a model's input without demonstrating the same change in every organ.

The 2023 organ-age proteomics study used organ-enriched blood proteins to construct estimates associated with disease and mortality outcomes. It helped describe heterogeneity between organs. Observational association still leaves a separate question: whether an intervention-induced change in an estimate predicts the clinical effect of that intervention.

Noise and trial design

Higgins-Chen and colleagues studied technical reliability in epigenetic clocks and developed principal-component methods to reduce noise. This is relevant whenever a claimed treatment effect is close to the variation introduced by the measurement process.

Imagine taking two aliquots from one blood sample. If their clock estimates differ, the difference cannot be a biological change in the person between visits. It tells researchers about technical variation. Repeatability needs to be established before interpreting a small shift over time.

Trials also need appropriate controls. An individual whose unusually high baseline estimate decreases at a second measurement might show regression toward the average. Randomised comparison, repeat measurements and consistent sample processing help distinguish that possibility from a treatment effect.

Testing many clocks and choosing a favourable result increases the opportunity for a chance finding. Analyses should disclose which clock was chosen before the data were examined and how multiple comparisons were handled.

What newer comparisons change

An August 2026 Nature Medicine study recalculated 16 clocks across 51 human intervention studies. The results varied by intervention and model; reporting only the clock with the largest age reduction would obscure that variation.

An October 2026 Aging Cell reanalysis found no additional statistically significant results when researchers applied further clocks to studies originally reporting one favourable clock. It recommends reliable principal-component clocks, agreement across models and measures trained on mortality or pace of ageing. Clinical endpoints still need to be measured.

The companion articles examine methylation measurements, blood proteins and animal survival studies.

The remaining connection

FDA guidance distinguishes biomarkers from clinical outcomes and explains that surrogate endpoints need evidence connecting them to clinical benefit in a defined context. A marker's ability to predict risk in untreated populations is useful, but it does not by itself validate that marker for every intervention.

A clock result becomes more persuasive when an adequately controlled study shows a reproducible change alongside improvements in relevant function, and follow-up establishes persistence. The explanation should retain the model name, sample type and actual measured outcome.

“The blood-protein model estimated a lower age” is a clear finding. Whether participants aged more slowly, became healthier or will live longer requires the corresponding evidence.

Sources

  1. Paper · 21 Oct 2013DNA methylation age of human tissues and cell types

    Primary multi-tissue methylation age-prediction paper.

    Checked 4 Oct 2026
  2. Paper · 9 Feb 2023Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial

    Post hoc methylation analysis from a randomised trial; different clocks gave different responses.

    Checked 4 Oct 2026
  3. Paper · 6 Dec 2023Organ aging signatures in the plasma proteome track health and disease

    Observational proteomic models and outcome associations; not intervention-surrogate validation.

    Checked 4 Oct 2026
  4. Paper · 15 Jul 2022A computational solution for bolstering reliability of epigenetic clocks: implications for clinical trials and longitudinal tracking

    Primary analysis of technical reliability and principal-component clock methods.

    Checked 4 Oct 2026
  5. Institutional source · Undated guidance pageFDA Facts: Biomarkers and Surrogate Endpoints

    Explains biomarker, surrogate and clinical endpoint distinctions.

    Checked 4 Oct 2026
  6. Paper · 21 Aug 2026Responsiveness of epigenetic aging biomarkers to longevity interventions in humans

    TranslAGE harmonised 51 intervention studies, 16 clocks and 94 methylation biomarkers; responsiveness does not constitute validated surrogacy.

    Checked 24 Oct 2026
  7. Paper · 8 Oct 2026When to Trust Epigenetic Clocks: Avoiding False Positives in Aging Interventions

    Tests disagreements across clock models; recommends reliability, outcome-trained clocks and concordance rather than selecting one favourable result.

    Checked 24 Oct 2026

Search the publication

Search programme histories and research articles.